Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases

• Published in: ESMO open Vol. 6; no. 2; p. 100057
• Main Authors: Steindl, A., Alpar, D., Heller, G., Mair, M.J., Gatterbauer, B., Dieckmann, K., Widhalm, G., Hainfellner, J.A., Schmidinger, M., Bock, C., Müllauer, L., Preusser, M., Berghoff, A.S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2021; Elsevier
• Subjects: brain metastases of renal cell carcinoma; Original Research; tumor microenvironment in renal cell carcinoma; tumor mutational burden in brain metastases; tumor-infiltrating lymphocytes in brain metastases; tumor mutational burden in brain metastases; brain metastases of renal cell carcinoma; tumor-infiltrating lymphocytes in brain metastases; tumor microenvironment in renal cell carcinoma
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1016/j.esmoop.2021.100057

Tumor mutational burden (TMB) and density of tumor-infiltrating lymphocytes (TIL) have been postulated as predictive biomarkers for immunotherapy. Therefore, we investigated the concordance of TMB and TIL of primary/extracranial renal cell carcinoma (RCC) specimens and matched brain metastases (BM). Twenty specimens from 10 patients were retrieved from the Vienna Brain Metastasis Registry (6/10 primary tumor, 4/10 lung metastasis, 10/10 matched BM). TMB was assessed using the TruSight Oncology 500 gene panel with libraries sequenced on a NextSeq instrument. TIL subsets (CD3+, CD8+, CD45RO+, FOXP3+, PD-L1+) were investigated using immunohistochemistry (Ventana Benchmark Ultra system) and automated tissue analysis (Definiens software). No significant difference in TMB, CD3+, CD8+, CD45RO+, FOXP3+ or PD-L1+ expression was observed between extracranial and matched intracranial specimens (P > 0.05). Higher CD8+ TIL (P = 0.053) and CD45RO+ TIL (P = 0.030) densities in the primary tumor compared with the intracranial samples were observed in specimens collected after exposure to systemic treatment. Neither extracranial sample origin (lung metastasis versus primary RCC) nor extracranial disease status at BM diagnosis (progressive versus stable disease) were significantly associated with TMB or TIL densities in extracranial and intracranial samples (P > 0.05). No significant correlation was found between the median differences of TMB or TIL densities from extracranial to intracranial samples and BM-free survival. The comparable immunological microenvironment of extra- and intracranial tumor samples in our study underscores the immunological activation also in BM from RCC, and therefore, supports the development of immune modulatory treatments also in patients with brain metastatic RCC. •Immunological microenvironment characteristics were comparable in extra- and intracranial RCC samples.•Numerically higher CD45RO+ and CD8+ TIL densities in extracranial compared to intracranial samples after systemic therapy.•The inflammatory microenvironment is a promising therapeutic target in RCC BM.